What have we learned from gene expression profiles in Huntington's disease?

被引:109
|
作者
Seredenina, Tamara [1 ]
Luthi-Carter, Ruth [1 ]
机构
[1] Ecole Polytech Fed Lausanne, Lab Funct Neurogen, CH-1015 Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
Polyglutamine disease; huntingtin; Transcriptomic profiling; Striatum; Cortex; Muscle; Blood; Microarray; Biomarker; HISTONE DEACETYLASE INHIBITORS; NEURONAL INTRANUCLEAR INCLUSIONS; CRE-MEDIATED TRANSCRIPTION; ADENOSINE A(2A) RECEPTORS; TRANSGENIC MOUSE MODELS; CELL-CELL INTERACTIONS; MUTANT-HUNTINGTIN; SYNAPTIC PLASTICITY; BINDING-PROTEIN; MESSENGER-RNA;
D O I
10.1016/j.nbd.2011.07.001
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The availability of many high-quality genome-wide expression datasets has provided an exciting and unique opportunity to better understand the molecular etiology of Huntington's disease. Combining this knowledge with other aspects of huntingtin biology and disease modification screens is yielding important new insights into disease-mitigating therapeutic strategies. Having followed this line of inquiry for some time, we note that there have been a number of surprises regarding the subsequently confirmed relationships between gene expression and disease etiology. Moreover, the complexity and sheer number of proposed mechanisms by which huntingtin can perturb gene expression continues to expand. Nonetheless, ongoing efforts to enthusiastically and critically evaluate the relationships between HD pathobiology and gene expression promise to deliver accurate predictions as to which therapeutic strategies will be most effective. An exciting new arm of this research also demonstrates the power of pharmacogenomics to detect (and rule out) important neuroprotective gene expression effects. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:83 / 98
页数:16
相关论文
共 50 条
  • [1] Taming the Huntington's Disease Proteome: What Have We Learned?
    Seeley, Connor
    Kegel-Gleason, Kimberly B.
    JOURNAL OF HUNTINGTONS DISEASE, 2021, 10 (02) : 239 - 257
  • [2] Huntington's disease: What we learned from the original essay
    Okun, MS
    NEUROLOGIST, 2003, 9 (04) : 175 - 179
  • [3] Alcoholism and gene expression: What have we learned?
    Mayfield, R. Dayne
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2006, 30 (09) : 54A - 54A
  • [4] Preclinical and Clinical Investigations of Mood Stabilizers for Huntington's Disease: What Have We Learned?
    Scheuing, Lisa
    Chiu, Chi-Tso
    Liao, Hsiao-Mei
    Linares, Gabriel R.
    Chuang, De-Maw
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2014, 10 (09): : 1024 - 1038
  • [5] Gene expression profiling in pediatric rheumatic disease:: what have we learned?: what can we learn?
    Jarvis, JN
    CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (05) : 606 - 611
  • [6] Gene expression in human sepsis: what have we learned?
    Russell, James A.
    CRITICAL CARE, 2011, 15 (01):
  • [7] Gene expression in human sepsis: what have we learned?
    James A Russell
    Critical Care, 15
  • [8] Peyronie's Disease: What Have We Learned?
    Levine, Laurence A.
    JOURNAL OF SEXUAL MEDICINE, 2004, 1 : 9 - 11
  • [9] Large Animal Models of Huntington's Disease: What We Have Learned and Where We Need to Go Next
    Howland, David
    Ellederova, Zdenka
    Aronin, Neil
    Fernau, Deborah
    Gallagher, Jill
    Taylor, Amanda
    Hennebold, Jon
    Weiss, Alison R.
    Gray-Edwards, Heather
    McBride, Jodi
    JOURNAL OF HUNTINGTONS DISEASE, 2020, 9 (03) : 201 - 216
  • [10] Chromosomal profiles of gene expression in Huntington's disease
    Anderson, Alexander N.
    Roncaroli, Federico
    Hodges, Angela
    Deprez, Manuel
    Turkheimer, Federico E.
    BRAIN, 2008, 131 : 381 - 388